Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-931 in Metastatic Solid Tumors
NCT03261947Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of simurosertib in metastatic colorectal cancer (mCRC), Esophageal Squamous Cell Carcinoma (ESCC), squamous cell lung cancer (SCLC) and 1 more (5 cohorts), sponsored by Millennium Pharmaceuticals. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities, Percentage of Participants With Treatment Emergent Adverse Events up to 15 months and 1 more. Started Oct 2017; status: completed.
02
Drugs
simurosertib
03
Conditions
metastatic colorectal cancer (mCRC)Esophageal Squamous Cell Carcinoma (ESCC)squamous cell lung cancer (SCLC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03261947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261947.